|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.03.26 - 13:09
|
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025....
|
|
|
24.02.26 - 14:06
|
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes....
|
|
|
23.02.26 - 22:09
|
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time....
|
|
|
|
|
12.01.26 - 14:09
|
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025....
|
|
|
01.12.25 - 15:06
|
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO (Business Wire)
|
|
|
Industry veteran brings two decades of platform commercialization experience in cell therapy, bioprocessing, and bioanalytics as Cellares prepares to support multiple clinical trials in 2026
Appointment follows five global manufacturing agreements with partners, including Bristol Myers Squibb, Kite, and leading academic institutions, as well as the FDA's first Advanced Manufacturing Technology designation for a cell therapy manufacturing platform.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad's appointment is key to driving the commercial expansion and pipeline gro...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.11.25 - 22:09
|
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
